Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 August 2022 | Story André Damons | Photo André Damons
UFS Nuclear Medicine
The team of doctors in the Department of Nuclear Medicine behind the success story are, from the left (standing): Dr Osayande Evbuomwan, nuclear medicine specialist and Senior Lecturer; Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS; and Dr Walter Endres, nuclear medicine registrar. In front is Dr Tebatso Tebeila, nuclear medicine registrar.

The University of the Free State (UFS) Department of Nuclear Medicine is proud to announce the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

This is a proud and happy moment for the department and the UFS, which started this treatment just over a year ago. The university and the Free State province are now joining other South African medical universities, such as the University of Pretoria, and other provinces in using this method to treat MCRPC patients. Lutetium 177 PSMA (Lu-177 PSMA) therapy is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy.

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the department is proud to be able to offer this treatment option to some of these patients. “It is a big win for the Free State and our oncology patients to be able to offer these expert services.” The UFS and Universitas Academic Hospital have now been able to join up with other academic institutions and hospitals in other provinces to offer these services. So far, three patients have been offered this therapeutic option, with the third patient currently undergoing his treatment.

Funds and equipment for proper treatment selection are needed

The expertise is no longer an issue for the UFS, as Dr Osayande Evbuomwan, nuclear medicine specialist and consultant, was trained and exposed to this therapy at the University of the Witwatersrand during his training as a nuclear medicine resident. Current registrars in the Department of Nuclear Medicine at the UFS are also being trained in the application of this treatment modality. However, proper patient selection is key in the management of these cases with Lu 177 PSMA. Without a PET/CT camera, it is challenging to appropriately select the patients who are most likely to respond to this therapy. This is an example of how PET/CT is crucial in the management and monitoring of oncology patients.

Both Drs Engelbrecht and Evbuomwan hope that the training of more registrars will increase their department’s capacity to treat more patients. They also hope that funds will be made available to acquire a much-needed PET/CT camera, which will greatly assist them in identifying the correct patients in need of this treatment. 

With the permission of the patient, the images above show the dramatic treatment response following Lu-177 PSMA therapy. The images on the left show widespread bone disease from the prostate cancer, including the skull. The images on the right show the dramatic response after completing four cycles of Lu 177 PSMA, with the normal excretion of the radiotracer seen in the liver, kidneys, and bladder.


Treatment puts the department, UFS, and hospital on the map

According to Dr Evbuomwan, the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country. Says he: “It also creates an avenue for us to gather data for training, research purposes, and publications. We are now able to offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some of these patients will no longer have to travel to other provinces to receive this treatment.”


“We are also well aware that not every patient will respond this way; however, proper patient selection is key in identifying responders – an area that is still being researched. We also do not know how long these patients will have their disease under control after the treatment. Nuclear medicine’s greatest cancer therapy success story is the treatment of well-differentiated thyroid cancer with radioactive iodine.” 

“After treatment, most of these patients remain cancer-free for a very long period of time, if not for life. With continuing research in the field of MCRPC radioligand therapy, we aim to improve the treatment modality, hopefully getting it to the success level of thyroid cancer therapy.”

 

News Archive

Her mission: Looking for viruses
2017-10-03

Description: Burt readmore Tags: Prof Felicity Burt, Felicity Burt, inaugural lecture, medical virology, UFS Faculty of Health Sciences, arboviruses 

Prof Felicity Burt delivering her inaugural lecture,
Catching a Virus
Photo: Stephen Collett

“Preparing and presenting an inaugural lecture is an opportunity to look back at one’s career and to enjoy previous highlights and achievements; to share these, not only with colleagues, but also with family and friends.”

This is according to Prof Felicity Burt, who recently presented her inaugural lecture, Catching a Virus. Prof Burt is a professor in medical virology in the Faculty of Health Sciences at the University of the Free State (UFS). It may sound ominous, but it is a story about identifying viruses, and finding and stopping them in their tracks in nature.

Research focus on arbo- and zoonotic viruses 
“My research focuses on arboviruses and zoonotic viruses,” said Prof Burt. “Arboviruses are viruses that are transmitted by insect vectors, such as mosquitoes, ticks, midges or sandflies, whereas zoonotic viruses are naturally transmitted from animals to humans. However, there is a considerable overlap between these two groups.” The research looks at host responses, virus discovery and surveillance in order to identify which of the viruses in circulation have the potential to cause human diseases.

“Emerging and re-emerging viruses have significant implications for public health,” said Prof Burt at the start of her lecture. She also stated that there have been disease outbreaks of unprecedented magnitude, which have spread and established in distinct geographic regions. “Many of these emerging viruses are transmitted by vectors or are spread to humans from animals. These viruses can cause significant diseases in humans,” said Prof Burt. 

There are many reasons why these viruses re-emerge, such as global warming, human invasion in forested areas, changes in agricultural practices, international travel, as well as the illegal movement of animals. Prof Burt used the Zika virus as an example of a recent emerging virus. 

More than 20 years’ experience 

With more than 20 years’ experience and a PhD in medical virology from the University of the Witwatersrand, Prof Burt is a renowned specialist. She has worked in the Special Pathogens Unit at the National Institute for Communicable Diseases, and was a member of various teams responding to outbreaks of Ebola and Rift Valley fever in Africa and Saudi Arabia, respectively. She is co-author of more than 51 articles in international scientific journals, as well as six chapters on arboviruses. In 2016, she was awarded a SARChl research chair by the South African Research Chair Initiative for her research on vector-borne and zoonotic diseases.

Click here to read the full lecture.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept